Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.70 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.70 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.70 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.70 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.70 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.70 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3951457 | 0.90 | GABRA1 (0.74) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7395749 | 0.89 | GABRA1 (0.73) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Hydrochloric Acid SCHEMBL7443756 | 0.89 | GABRA1 (0.65) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Dimdazenil SCHEMBL3088188 | 0.88 | GABRA1 (0.70) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7428610 | 0.87 | GABRA1 (0.69) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7391222 | 0.85 | GABRA1 (0.61) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7391832 | 0.85 | GABRA1 (0.72) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7393803 | 0.84 | GABRA1 (0.66) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7390153 | 0.84 | GABRA1 (0.70) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7392770 | 0.84 | GABRA1 (0.65) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190435-B1 | TREATMENT OF SLEEP DISORDERS | EVOTEC INT GMBH (DE) | 2018-05-30 | — | — | EP | disclosed |
| WO-2009024324-A9 | TREATMENT OF SLEEP DISORDERS | EVOTEC NEUROSCIENCES GMBH (DE) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009024324-A3 | TREATMENT OF SLEEP DISORDERS | EVOTEC NEUROSCIENCES GMBH (DE) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009024325-A2 | TREATMENT OF SLEEP DISORDERS | EVOTEC NEUROSCIENCES GMBH (DE) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009024324-A2 | TREATMENT OF SLEEP DISORDERS | EVOTEC NEUROSCIENCES GMBH (DE) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009024324-A2 | TREATMENT OF SLEEP DISORDERS | EVOTEC NEUROSCIENCES GMBH (DE) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009024324-A2 | TREATMENT OF SLEEP DISORDERS | EVOTEC NEUROSCIENCES GMBH (DE) | 2009-02-26 | — | — | WO | disclosed |
| EP-0672666-B1 | Imidazodiazepins | HOFFMANN LA ROCHE (CH) | 2001-07-25 | — | — | EP | disclosed |
| US-5665718-A | ANXIOLYTIC, ANTICONVULSANT, MUSCLE RELAXANT, SEDATIVE, HYPNOTIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1997-09-09 | — | — | US | disclosed |
| EP-0672666-A2 | Imidazodiazepins | F. Hoffmann-La Roche AG (CH) | 1995-09-20 | — | — | EP | disclosed |